Clinical Trial Search

Primary: Percentage of Participants With Clinical Improvement in the 3 General Categories of Pain, Inflammation, and Limb Function Based on the Investigator's Overall Assessment…

Primary: Description of the Clinical and Epidemiological Profile of Patients With Infection — 92; 26; 25; 21 Participants

Primary: Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to Adverse Events (AEs) — 1 incidence

Primary: Number of Participants With the Presence of Post-Operative Infection — 2; 2 Participants

Primary: Systemic Vancomycin Level - Start of Case — 27.98; 0 ug/mL

Primary: Occurrence of Post-chemotherapy Bacteremia — 22; 81 Participants

Primary: Percentage of Participants With Clinical Response at Day 42 in the Clinically Evaluable (CE) Population — 97.0; 87.5; 0.0; 12.5 percentage of participants

Primary: Extensive Radiographic Osteonecrosis — 20; 21; 1; 2 Participants — p=0.7139

Primary: Length of Stay (LOS) in Those With 14 Confirmed Catheter Related Infection Cases — 124; 208 HOURS

Primary: Clinical Success at 6 Months — 18; 9; 3 Participants

Primary: Mortality — 11 Participants

Primary: T2* Relaxation Time of Bone Sarcomas and Osteomyelitis Subjects — 7.3; 7.7 milliseconds

Primary: Median Dose of Dalteparin Required to Achieve Prespecified Therapeutic Anti- Factor Xa Level — 125 IU/mL

Primary: The Frequency of Definite Failure of Infection Treatment. — 67; 74 Participants

Primary: The Time to Resolution of Symptoms, Defined as Acute Otitis Media-Severity of Symptoms (AOM-SOS) Score of 0 or 1, According to Treatment Assignment — 20; 9; 1; 2…

Primary: Incidence of Surgical Site Infection (SSI) Relating to Intramedullary Nailing for Fixation of Diaphyseal Femoral and Tibial Fractures — 26; 195 Participants

Primary: Amount of Bone Density Lost (%) From pre-to Post-operative DXA Scan — 0.043; -0.025 percent change

Primary: Number of Participants With Adverse Events — 5; 4; 1; 6 participants

Primary: Quantify the Tolerability of Tedizolid for Bone and Joint Infections, Both Hardware and Non-hardware Associated — 0; 0 participants

Primary: Number of Blood Samples With High Levels of Absorbance Via ELISA for Patients (Greater Than 1.5 Ratio Compared to Control Human Serum) — 48; 53 blood draw samples

Primary: Lumbar Spine Bone Mineral Content — 41.4; 38.7 Average grams

Primary: Incidence of Surgical Site Infection During the Post-operative Follow-up Period — 0; 0; 0 participants

Primary: Adverse Events — 10; 5; 1; 0 Participants

Primary: Number of Participants With a Pathogen Identified by the Initial Karius Test (IP1) and Standard Culture Methods — 23; 26; 15 Participants

Primary: Change in Bone Mineral Density in Response to Pamidronate — -3.54; -4.98 Z-score

Primary: Compare Differences in HRQOL Scores Between Outpatient Versus Inpatient Management — 70.1; 68.7 score on a scale

Primary: Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability) Following Multiple Doses of Intravenous AP-Sa02. — 17; 10; 6; 2 number of…

Primary: Desirability of Outcome Ranking (DOOR) — 49; 49; 34; 37 Participants

Primary: Change in Middle Ear Effusion Over Four Weeks Following an Episode of Acute Otitis Media — 26; 16; 12; 22 Ears — p=0.02

Primary: Shift From Baseline in Distortion Product Otoacoustic Emission at TOC Visit — 2; 1; 0; 0 Participants